Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, non-randomized, dose-escalation study to evaluate the safety
and tolerability, the maximum tolerated dose (MTD) and the dose limited toxicity(DLT) of
LY01610 monotherapy and combine with 5-Fu in patients with advanced solid tumors.
Additionally, the pharmacokinetics and preliminary efficacy of LY01610 monotherapy and
combine with 5-Fu will be investigated in this study.